Barclays Boosts Phibro Animal Health (NASDAQ:PAHC) Price Target to $22.00

Phibro Animal Health (NASDAQ:PAHC) had its price target lifted by equities research analysts at Barclays from $20.00 to $22.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price objective indicates a potential downside of 15.77% from the stock’s previous close.

A number of other equities research analysts have also weighed in on PAHC. StockNews.com lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 6th. Morgan Stanley increased their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus price target of $21.00.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $26.12 on Monday. Phibro Animal Health has a 12 month low of $11.24 and a 12 month high of $26.49. The stock has a fifty day moving average price of $21.95 and a 200-day moving average price of $21.75. The company has a current ratio of 3.20, a quick ratio of 1.69 and a debt-to-equity ratio of 2.99. The firm has a market cap of $1.06 billion, a PE ratio of 54.42, a P/E/G ratio of 0.53 and a beta of 0.52.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. Equities research analysts predict that Phibro Animal Health will post 1.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. acquired a new stake in shares of Phibro Animal Health during the 4th quarter worth approximately $2,205,000. Jacobs Levy Equity Management Inc. boosted its holdings in Phibro Animal Health by 116.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock worth $4,330,000 after buying an additional 103,491 shares in the last quarter. Prudential Financial Inc. grew its position in Phibro Animal Health by 405.8% during the fourth quarter. Prudential Financial Inc. now owns 120,655 shares of the company’s stock valued at $2,534,000 after buying an additional 96,800 shares during the period. American Century Companies Inc. increased its holdings in Phibro Animal Health by 18.0% in the fourth quarter. American Century Companies Inc. now owns 635,599 shares of the company’s stock valued at $13,348,000 after buying an additional 96,787 shares in the last quarter. Finally, Algert Global LLC raised its position in shares of Phibro Animal Health by 521.1% in the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after acquiring an additional 59,850 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.